These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14979239)

  • 41. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Controlling spending for prescription drugs.
    Altman SH; Parks-Thomas C
    N Engl J Med; 2002 Mar; 346(11):855-6. PubMed ID: 11893800
    [No Abstract]   [Full Text] [Related]  

  • 43. Inadequate prescription-drug coverage for Medicare enrollees--a call to action.
    Soumerai SB; Ross-Degnan D
    N Engl J Med; 1999 Mar; 340(9):722-8. PubMed ID: 10053183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
    Mullins CD; Palumbo FB; Saba M
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug usage review. Part one: designing the BC Pharmacare program.
    Hlynka JN; Danforth DH
    Can Pharm J; 1981 Nov; 114(11):421-3. PubMed ID: 10253376
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
    MacEachern L
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medicare risk programs and pharmacy benefits managers.
    Herzfeld J
    Med Interface; 1996 Dec; 9(12):75-8. PubMed ID: 10172875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health plans step up management of drugs under medical benefit.
    Reinke T
    Manag Care; 2014 Jul; 23(7):6-7. PubMed ID: 25202798
    [No Abstract]   [Full Text] [Related]  

  • 50. Incentives in the Medicare prescription drug benefit.
    Natl Bur Econ Res Bull Aging Health; 2006; (15):1-2. PubMed ID: 16805056
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
    Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specialty pharmacy management adjusts to new financial realities.
    Reinke T
    Manag Care; 2013 Apr; 22(4):13-4. PubMed ID: 23678558
    [No Abstract]   [Full Text] [Related]  

  • 54. The formulary files. PBMs report increase in drug margins.
    Manag Care; 2006 Jan; 15(1):59. PubMed ID: 16502778
    [No Abstract]   [Full Text] [Related]  

  • 55. Naltrexone and pharmacy benefit management.
    Harris KM; Thomas C
    J Addict Dis; 2004; 23(4):11-29. PubMed ID: 15339711
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complying with state and federal regulations on essential drug benefits: implementing the Affordable Care Act.
    Cohen JP; Felix A; Vasiadi M
    Am J Manag Care; 2014 Feb; 20(2):153-8. PubMed ID: 24738533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-28. PubMed ID: 21374839
    [No Abstract]   [Full Text] [Related]  

  • 60. Capitation payment for pharmacy: a head start on fair return?
    Tidball P
    Can Pharm J; 1982 Jul; 115(7):271-3. PubMed ID: 10256465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.